REGULATORY
Academic Experts Throw Candid Questions on Industry Structure, Pricing: Hearing
Academic experts on the health ministry’s revamped panel on comprehensive measures for pharmaceuticals raised many frank opinions and questions regarding the industry’s structure and the nature of drug pricing reforms at a hearing on September 22. At the hearing with…
To read the full story
Related Article
REGULATORY
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
- MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
- LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
- LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





